Stockscreener 앱 받기
724.54
1.39%
9.95
시장 영업 전:
723.54
-1.00
-0.14%
Lilly Eli Co 주식(LLY)의 최신 뉴스
Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms - Benzinga
Eli Lilly and Company (LLY) Plans $6.5B Investment to Bolster Pipeline Production - Yahoo Finance
Are These GLP-1 Trial Results About to Send Eli Lilly's Stock Soaring? - MSN
West Branch Capital LLC Has $6.42 Million Stock Position in Eli Lilly and Company $LLY - MarketBeat
Positive Report for Eli Lilly & Co (LLY) from CFRA - The Globe and Mail
Precision Trading with Eli Lilly And Company (LLY) Risk Zones - news.stocktradersdaily.com
Did European and U.S. Drug Approvals Plus Texas Expansion Just Shift Eli Lilly’s (LLY) Investment Narrative? - simplywall.st
How Investors May Respond To Alexandria Real Estate Equities (ARE) Expanding Biotech Innovation Hubs With Eli Lilly - simplywall.st
Eli Lilly and Company $LLY Shares Sold by State of Alaska Department of Revenue - MarketBeat
True North Advisors LLC Has $2.30 Million Stake in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly (LLY) Announces New Innovation Hub as President Trump Threatens Pharma Tariffs - TipRanks
Eli Lilly terminates trial of Zepbound and muscle-sparing combo - Clinical Trials Arena
Eli Lilly and Company (NYSE:LLY) Shares Up 1.4%Here's What Happened - MarketBeat
Alexandria, Eli Lilly Open Torrey Pines Innovation Hub - Connect CRE
Eli Lilly, Pfizer, Amgen Stocks Rise After Trump’s 100% Pharma Tariff Threat. Here’s Why. - Barron's
Why Lilly chose Houston for $6.5B plant - KHOU
Eli Lilly upgraded at CFRA as minimal impact seen from pharma tariffs - Seeking Alpha
Eli Lilly, Intel, Paccar, GlobalFoundries, Boeing, AppLovin, Costco, Electronic Arts, and More Movers - Barron's
ELI LILLY AND COMPANY (LLY) - MSN
Eli Lilly, Amgen tout U.S. investments as Trump imposes 100% pharma tariffs - MSN
Eli Lilly’s New Study on LY3537031: A Potential Game-Changer for Renal Impairment Treatment? - TipRanks
FDA Approves Eli Lilly's Drug For Advanced Breast Cancer - AOL.com
Global drugmakers rush to boost US presence as tariff threat looms - Reuters
Eli Lilly (LLY) Opens San Diego Innovation Hub Despite Trump Tariff Threats - parameter.io
Wells Fargo Reiterates Buy Rating on Eli Lilly and Company Stock, Maintains PT at $1,000 - Yahoo Finance
Global markets live: Boeing, Eli Lilly, Microsoft, Amazon, Eni… - MarketScreener
Eli Lilly opens incubator site in San Diego, with 'several' biotechs already on board - Fierce Biotech
Eli Lilly and Company ($LLY) Stock: Halts Key Trial for Obesity Drug Combo - CoinCentral
Eli Lilly opens new Gateway Labs site in San Diego - MarketScreener
Lilly opens new biotech innovation hub in San Diego By Investing.com - Investing.com Canada
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock - Yahoo Finance
Jim Cramer Asserts You’ve “Gotta Stick With” Eli Lilly and Company (LLY) - Yahoo Finance
Eli Lilly, Pfizer Stocks Rise After Trump’s 100% Pharma Tariff Threat. Here’s Why. - MSN
Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystem - Eli Lilly and Company
Meyer Handelman Co. Reduces Stock Position in Eli Lilly and Company $LLY - MarketBeat
Why Is Eli Lilly’s Stock Rising Premarket? - Stocktwits
Eli Lilly’s New Study on LY3537031: A Potential Game-Changer? - TipRanks
Eli Lilly halts trial of investigational muscle-preserving drug with Zepbound - The Pharma Letter
Eli Lilly receives taxpayer funds to expand manufacturing in Texas - The Black Chronicle
Eli Lilly's GLP-1 Pill Just Beat Out Novo Nordisk's in a Test. Here's 1 Thing Investors Need to Know. - Yahoo Finance
Eli Lilly, Merck, Pfizer Stocks Rise After Trump Unveils Pharma Tariffs - The Wall Street Journal
US FDA approves Eli Lilly's therapy for advanced breast cancer - Reuters
How Eli Lilly And Company (LLY) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Eli Lilly says EC grants marketing authorization for Kisunla - TipRanks
Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease - Eli Lilly and Company
Eli Lilly and Company (NYSE:LLY) Stock Price Down 3.8%Time to Sell? - MarketBeat
Eli Lilly (LLY) Stock Trades Down, Here Is Why - TradingView
Eli Lilly Plans $6.5B Factory in Texas - Thomasnet
Eli Lilly Presses Pause On Zepbound-Bimagrumab Diabetes Study - Yahoo Finance
Eli Lilly's oral SERD Inluriyo passes muster with FDA in breast cancer - Fierce Pharma
Eli Lilly wins approval of imlunestrant for breast cancer - Seeking Alpha
Celltrion pays $330M for Eli Lilly plant to avoid tariffs, boost output - NJBIZ
Eli Lilly (LLY) to Build $6.5 Billion Manufacturing Plant in Texas - TipRanks
U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer - Eli Lilly and Company
Lilly CEO wants to tap Houston's chemicals labor pool for drugmaking - The Business Journals
Lilly Is Angling For Approval Of Its Obesity Pill. Is It Now A Buy? - Investor's Business Daily
$6.5 billion pharmaceutical plant planned for Lake Houston development - CultureMap Houston
1.11%
0.77%
자본화:
|
볼륨(24시간):